Micafungin in the treatment of invasive fungal infection in an infant with extracorporeal
Enferm Infecc Microbiol Clin. 2017 Aug-Sep;35(7):466-467.
doi: 10.1016/j.eimc.2016.10.005.
Epub 2016 Nov 16.
[Article in
English,
Spanish]
Affiliations
- 1 Pediatric Intensive Care Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
- 2 Pharmacy Service, Hospital Sant Joan de Déu, Barcelona, Spain. Electronic address: ijordan@hsjdbcn.org.
No abstract available
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Antifungal Agents
-
Biofilms / drug effects
-
Candida tropicalis / drug effects
-
Candida tropicalis / isolation & purification*
-
Candida tropicalis / physiology
-
Candidemia / drug therapy*
-
Candidemia / etiology
-
Candidemia / microbiology
-
Combined Modality Therapy
-
Cross Infection / drug therapy*
-
Cross Infection / etiology
-
Cross Infection / microbiology
-
Equipment Contamination
-
Extracorporeal Membrane Oxygenation / adverse effects*
-
Female
-
Humans
-
Infant
-
Micafungin
-
Pneumonia, Necrotizing / complications
-
Pneumonia, Necrotizing / drug therapy
-
Pneumonia, Necrotizing / therapy
-
Pneumonia, Pneumococcal / complications
-
Pneumonia, Pneumococcal / drug therapy
-
Respiration, Artificial
-
Respiratory Distress Syndrome / etiology
-
Respiratory Distress Syndrome / therapy
-
Shock, Septic / etiology
-
Shock, Septic / therapy*
-
Superinfection / drug therapy
-
Superinfection / etiology*
-
Superinfection / microbiology
Substances
-
Anti-Bacterial Agents
-
Antifungal Agents
-
Micafungin